PAHC Q3 FY26: Net income up 151% YTD on margin gains; Brazil bans virginiamycin growth use

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 7, 2025 · ~1 min read

Key Changes

• high

  Brazil banned virginiamycin as a growth promoter effective April 27, 2026 with a 180-day transition. Company pursuing therapeutic indications expected during transition period.

  MD&A: Brazil virginiamycin regulatory action verify on EDGAR →
• high

  Nine-month net income rose 151% to $78.0M from $31.0M prior year, driven by 210bp gross margin expansion to 33.7% on favorable mix and pricing.

  MD&A: Nine-month results verify on EDGAR →
• medium

  Revolving credit facility expanded by $125M to $435M total capacity in April 2026, enhancing financial flexibility as working capital increased $102M year-over-year.

  MD&A: Revolving credit facility expansion verify on EDGAR →